nodes	percent_of_prediction	percent_of_DWPC	metapath
Molindone—HTR7—vas deferens—prostate cancer	0.0773	0.542	CbGeAlD
Molindone—HTR2A—urine—prostate cancer	0.012	0.0841	CbGeAlD
Molindone—CHRM1—prostate gland—prostate cancer	0.00811	0.0568	CbGeAlD
Molindone—Galactorrhoea—Conjugated Estrogens—prostate cancer	0.00617	0.0101	CcSEcCtD
Molindone—Pigmentation disorder—Capecitabine—prostate cancer	0.00599	0.00977	CcSEcCtD
Molindone—Disturbance in sexual arousal—Nilutamide—prostate cancer	0.0058	0.00946	CcSEcCtD
Molindone—Disturbance in sexual arousal—Flutamide—prostate cancer	0.00577	0.00942	CcSEcCtD
Molindone—Amenorrhoea—Ethinyl Estradiol—prostate cancer	0.00559	0.00912	CcSEcCtD
Molindone—Disturbance in sexual arousal—Estradiol valerate/Dienogest—prostate cancer	0.00545	0.00889	CcSEcCtD
Molindone—Pigmentation disorder—Prednisone—prostate cancer	0.00533	0.0087	CcSEcCtD
Molindone—Libido increased—Estradiol—prostate cancer	0.00527	0.0086	CcSEcCtD
Molindone—Gynaecomastia—Bicalutamide—prostate cancer	0.0052	0.00849	CcSEcCtD
Molindone—Disturbance in sexual arousal—Degarelix—prostate cancer	0.00518	0.00845	CcSEcCtD
Molindone—HTR7—epithelium—prostate cancer	0.00508	0.0356	CbGeAlD
Molindone—ADRA2A—prostate gland—prostate cancer	0.00507	0.0355	CbGeAlD
Molindone—Throat tightness—Etoposide—prostate cancer	0.00507	0.00827	CcSEcCtD
Molindone—Galactorrhoea—Estradiol—prostate cancer	0.00494	0.00806	CcSEcCtD
Molindone—HTR1A—renal system—prostate cancer	0.00493	0.0345	CbGeAlD
Molindone—HTR7—renal system—prostate cancer	0.00471	0.033	CbGeAlD
Molindone—Urinary retention—Cabazitaxel—prostate cancer	0.00468	0.00763	CcSEcCtD
Molindone—Amenorrhoea—Goserelin—prostate cancer	0.0046	0.00751	CcSEcCtD
Molindone—Weight decreased—Nilutamide—prostate cancer	0.00457	0.00746	CcSEcCtD
Molindone—Amenorrhoea—Conjugated Estrogens—prostate cancer	0.00456	0.00744	CcSEcCtD
Molindone—Drowsiness—Flutamide—prostate cancer	0.00448	0.00732	CcSEcCtD
Molindone—Weight increased—Estradiol valerate/Dienogest—prostate cancer	0.00432	0.00705	CcSEcCtD
Molindone—Weight decreased—Estradiol valerate/Dienogest—prostate cancer	0.00429	0.00701	CcSEcCtD
Molindone—ADRA2A—seminal vesicle—prostate cancer	0.00428	0.03	CbGeAlD
Molindone—Disturbance in sexual arousal—Bicalutamide—prostate cancer	0.00419	0.00683	CcSEcCtD
Molindone—Pigmentation disorder—Epirubicin—prostate cancer	0.00417	0.00681	CcSEcCtD
Molindone—Weight increased—Degarelix—prostate cancer	0.00411	0.0067	CcSEcCtD
Molindone—Weight decreased—Degarelix—prostate cancer	0.00408	0.00666	CcSEcCtD
Molindone—Urinary retention—Bicalutamide—prostate cancer	0.00401	0.00655	CcSEcCtD
Molindone—Pigmentation disorder—Doxorubicin—prostate cancer	0.00386	0.0063	CcSEcCtD
Molindone—Weight decreased—Cabazitaxel—prostate cancer	0.00385	0.00628	CcSEcCtD
Molindone—Muscle spasms—Estramustine—prostate cancer	0.00381	0.00622	CcSEcCtD
Molindone—Amenorrhoea—Estradiol—prostate cancer	0.00365	0.00595	CcSEcCtD
Molindone—Dysphagia—Bicalutamide—prostate cancer	0.00365	0.00595	CcSEcCtD
Molindone—Muscle spasms—Estrone—prostate cancer	0.00364	0.00594	CcSEcCtD
Molindone—Gynaecomastia—Goserelin—prostate cancer	0.00362	0.0059	CcSEcCtD
Molindone—Leukopenia—Estramustine—prostate cancer	0.00355	0.00579	CcSEcCtD
Molindone—Disturbance in sexual arousal—Ethinyl Estradiol—prostate cancer	0.00354	0.00577	CcSEcCtD
Molindone—Dyskinesia—Estradiol—prostate cancer	0.00341	0.00557	CcSEcCtD
Molindone—Amenorrhoea—Mitoxantrone—prostate cancer	0.0034	0.00555	CcSEcCtD
Molindone—ADRA2A—urethra—prostate cancer	0.00339	0.0238	CbGeAlD
Molindone—Weight increased—Bicalutamide—prostate cancer	0.00332	0.00542	CcSEcCtD
Molindone—Weight decreased—Bicalutamide—prostate cancer	0.0033	0.00538	CcSEcCtD
Molindone—Muscle spasms—Estradiol valerate/Dienogest—prostate cancer	0.00318	0.00519	CcSEcCtD
Molindone—HTR2A—epithelium—prostate cancer	0.00317	0.0222	CbGeAlD
Molindone—Leukopenia—Nilutamide—prostate cancer	0.00315	0.00514	CcSEcCtD
Molindone—Leukopenia—Flutamide—prostate cancer	0.00314	0.00512	CcSEcCtD
Molindone—HTR7—testis—prostate cancer	0.00304	0.0213	CbGeAlD
Molindone—Muscle spasms—Degarelix—prostate cancer	0.00302	0.00493	CcSEcCtD
Molindone—Vision blurred—Degarelix—prostate cancer	0.00296	0.00484	CcSEcCtD
Molindone—HTR2A—renal system—prostate cancer	0.00294	0.0206	CbGeAlD
Molindone—Dry mouth—Nilutamide—prostate cancer	0.00293	0.00478	CcSEcCtD
Molindone—Disturbance in sexual arousal—Goserelin—prostate cancer	0.00291	0.00475	CcSEcCtD
Molindone—Dyspnoea—Estramustine—prostate cancer	0.00289	0.00471	CcSEcCtD
Molindone—DRD2—testis—prostate cancer	0.00288	0.0202	CbGeAlD
Molindone—Gynaecomastia—Estradiol—prostate cancer	0.00287	0.00468	CcSEcCtD
Molindone—Muscle spasms—Cabazitaxel—prostate cancer	0.00285	0.00465	CcSEcCtD
Molindone—Weight increased—Ethinyl Estradiol—prostate cancer	0.00281	0.00458	CcSEcCtD
Molindone—Dyspnoea—Abiraterone—prostate cancer	0.0028	0.00457	CcSEcCtD
Molindone—Urinary retention—Goserelin—prostate cancer	0.00279	0.00455	CcSEcCtD
Molindone—Weight decreased—Ethinyl Estradiol—prostate cancer	0.00279	0.00455	CcSEcCtD
Molindone—Constipation—Abiraterone—prostate cancer	0.00269	0.00439	CcSEcCtD
Molindone—Leukopenia—Cabazitaxel—prostate cancer	0.00265	0.00433	CcSEcCtD
Molindone—Dry mouth—Degarelix—prostate cancer	0.00262	0.00427	CcSEcCtD
Molindone—Dyspnoea—Nilutamide—prostate cancer	0.00256	0.00418	CcSEcCtD
Molindone—Somnolence—Flutamide—prostate cancer	0.00254	0.00415	CcSEcCtD
Molindone—Dysphagia—Conjugated Estrogens—prostate cancer	0.00251	0.0041	CcSEcCtD
Molindone—Dry mouth—Cabazitaxel—prostate cancer	0.00247	0.00402	CcSEcCtD
Molindone—Constipation—Nilutamide—prostate cancer	0.00246	0.00401	CcSEcCtD
Molindone—Constipation—Flutamide—prostate cancer	0.00245	0.00399	CcSEcCtD
Molindone—Muscle spasms—Bicalutamide—prostate cancer	0.00244	0.00399	CcSEcCtD
Molindone—Hypotension—Degarelix—prostate cancer	0.0024	0.00391	CcSEcCtD
Molindone—Tachycardia—Cabazitaxel—prostate cancer	0.00236	0.00385	CcSEcCtD
Molindone—Amenorrhoea—Docetaxel—prostate cancer	0.00235	0.00383	CcSEcCtD
Molindone—Weight increased—Goserelin—prostate cancer	0.00231	0.00377	CcSEcCtD
Molindone—Disturbance in sexual arousal—Estradiol—prostate cancer	0.00231	0.00377	CcSEcCtD
Molindone—Dyspnoea—Degarelix—prostate cancer	0.00229	0.00373	CcSEcCtD
Molindone—Weight increased—Conjugated Estrogens—prostate cancer	0.00229	0.00373	CcSEcCtD
Molindone—Drowsiness—Goserelin—prostate cancer	0.00226	0.00369	CcSEcCtD
Molindone—Hypotension—Cabazitaxel—prostate cancer	0.00226	0.00369	CcSEcCtD
Molindone—ADRA2A—testis—prostate cancer	0.00223	0.0156	CbGeAlD
Molindone—Constipation—Degarelix—prostate cancer	0.00219	0.00358	CcSEcCtD
Molindone—Dyspnoea—Cabazitaxel—prostate cancer	0.00216	0.00352	CcSEcCtD
Molindone—Dry mouth—Bicalutamide—prostate cancer	0.00212	0.00345	CcSEcCtD
Molindone—Constipation—Cabazitaxel—prostate cancer	0.00207	0.00337	CcSEcCtD
Molindone—Muscle spasms—Ethinyl Estradiol—prostate cancer	0.00206	0.00337	CcSEcCtD
Molindone—Rash—Estramustine—prostate cancer	0.00204	0.00333	CcSEcCtD
Molindone—Dermatitis—Estramustine—prostate cancer	0.00204	0.00333	CcSEcCtD
Molindone—Amenorrhoea—Prednisone—prostate cancer	0.00203	0.00331	CcSEcCtD
Molindone—Dysphagia—Estradiol—prostate cancer	0.00201	0.00328	CcSEcCtD
Molindone—Rash—Abiraterone—prostate cancer	0.00198	0.00324	CcSEcCtD
Molindone—Dermatitis—Abiraterone—prostate cancer	0.00198	0.00323	CcSEcCtD
Molindone—Rash—Estrone—prostate cancer	0.00195	0.00318	CcSEcCtD
Molindone—Dermatitis—Estrone—prostate cancer	0.00195	0.00318	CcSEcCtD
Molindone—Nausea—Estramustine—prostate cancer	0.00192	0.00314	CcSEcCtD
Molindone—HTR2A—testis—prostate cancer	0.0019	0.0133	CbGeAlD
Molindone—Leukocytosis—Prednisone—prostate cancer	0.00189	0.00309	CcSEcCtD
Molindone—Dyspnoea—Bicalutamide—prostate cancer	0.00185	0.00302	CcSEcCtD
Molindone—Somnolence—Bicalutamide—prostate cancer	0.00184	0.00301	CcSEcCtD
Molindone—Nausea—Estrone—prostate cancer	0.00184	0.003	CcSEcCtD
Molindone—Weight increased—Estradiol—prostate cancer	0.00183	0.00299	CcSEcCtD
Molindone—Weight decreased—Estradiol—prostate cancer	0.00182	0.00297	CcSEcCtD
Molindone—Rash—Nilutamide—prostate cancer	0.00181	0.00296	CcSEcCtD
Molindone—Dermatitis—Nilutamide—prostate cancer	0.00181	0.00295	CcSEcCtD
Molindone—Rash—Flutamide—prostate cancer	0.0018	0.00294	CcSEcCtD
Molindone—Dermatitis—Flutamide—prostate cancer	0.0018	0.00294	CcSEcCtD
Molindone—Constipation—Bicalutamide—prostate cancer	0.00177	0.00289	CcSEcCtD
Molindone—Nausea—Nilutamide—prostate cancer	0.00171	0.00278	CcSEcCtD
Molindone—Weight increased—Mitoxantrone—prostate cancer	0.00171	0.00278	CcSEcCtD
Molindone—Rash—Estradiol valerate/Dienogest—prostate cancer	0.0017	0.00278	CcSEcCtD
Molindone—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.0017	0.00277	CcSEcCtD
Molindone—Muscle spasms—Goserelin—prostate cancer	0.0017	0.00277	CcSEcCtD
Molindone—Nausea—Flutamide—prostate cancer	0.0017	0.00277	CcSEcCtD
Molindone—Weight decreased—Mitoxantrone—prostate cancer	0.0017	0.00277	CcSEcCtD
Molindone—Muscle spasms—Conjugated Estrogens—prostate cancer	0.00168	0.00275	CcSEcCtD
Molindone—Drowsiness—Mitoxantrone—prostate cancer	0.00167	0.00273	CcSEcCtD
Molindone—Vision blurred—Goserelin—prostate cancer	0.00167	0.00272	CcSEcCtD
Molindone—Vision blurred—Conjugated Estrogens—prostate cancer	0.00165	0.00269	CcSEcCtD
Molindone—Rash—Degarelix—prostate cancer	0.00162	0.00264	CcSEcCtD
Molindone—ADRA2A—lymph node—prostate cancer	0.00162	0.0113	CbGeAlD
Molindone—Dermatitis—Degarelix—prostate cancer	0.00162	0.00264	CcSEcCtD
Molindone—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.0016	0.00262	CcSEcCtD
Molindone—Amenorrhoea—Epirubicin—prostate cancer	0.00158	0.00259	CcSEcCtD
Molindone—Leukopenia—Goserelin—prostate cancer	0.00158	0.00258	CcSEcCtD
Molindone—Dysphagia—Etoposide—prostate cancer	0.00156	0.00254	CcSEcCtD
Molindone—Hyperkinesia—Prednisone—prostate cancer	0.00155	0.00253	CcSEcCtD
Molindone—Euphoric mood—Prednisone—prostate cancer	0.00153	0.0025	CcSEcCtD
Molindone—Nausea—Degarelix—prostate cancer	0.00152	0.00249	CcSEcCtD
Molindone—Constipation—Ethinyl Estradiol—prostate cancer	0.0015	0.00245	CcSEcCtD
Molindone—Dyskinesia—Epirubicin—prostate cancer	0.00148	0.00242	CcSEcCtD
Molindone—Dry mouth—Goserelin—prostate cancer	0.00147	0.0024	CcSEcCtD
Molindone—Amenorrhoea—Doxorubicin—prostate cancer	0.00147	0.00239	CcSEcCtD
Molindone—Disturbance in sexual arousal—Capecitabine—prostate cancer	0.00144	0.00235	CcSEcCtD
Molindone—Nausea—Cabazitaxel—prostate cancer	0.00144	0.00234	CcSEcCtD
Molindone—Tachycardia—Goserelin—prostate cancer	0.00141	0.0023	CcSEcCtD
Molindone—Tachycardia—Conjugated Estrogens—prostate cancer	0.00139	0.00228	CcSEcCtD
Molindone—Urinary retention—Capecitabine—prostate cancer	0.00138	0.00225	CcSEcCtD
Molindone—Dyskinesia—Doxorubicin—prostate cancer	0.00137	0.00224	CcSEcCtD
Molindone—Salivary hypersecretion—Epirubicin—prostate cancer	0.00135	0.00221	CcSEcCtD
Molindone—Hypotension—Goserelin—prostate cancer	0.00135	0.0022	CcSEcCtD
Molindone—Muscle spasms—Estradiol—prostate cancer	0.00135	0.0022	CcSEcCtD
Molindone—Hypotension—Conjugated Estrogens—prostate cancer	0.00134	0.00218	CcSEcCtD
Molindone—Tremor—Estradiol—prostate cancer	0.00131	0.00214	CcSEcCtD
Molindone—Rash—Bicalutamide—prostate cancer	0.00131	0.00213	CcSEcCtD
Molindone—Dermatitis—Bicalutamide—prostate cancer	0.00131	0.00213	CcSEcCtD
Molindone—Dysphagia—Docetaxel—prostate cancer	0.0013	0.00211	CcSEcCtD
Molindone—Agitation—Estradiol—prostate cancer	0.00129	0.0021	CcSEcCtD
Molindone—Dyspnoea—Goserelin—prostate cancer	0.00129	0.0021	CcSEcCtD
Molindone—Somnolence—Goserelin—prostate cancer	0.00128	0.00209	CcSEcCtD
Molindone—Dyspnoea—Conjugated Estrogens—prostate cancer	0.00127	0.00208	CcSEcCtD
Molindone—Somnolence—Conjugated Estrogens—prostate cancer	0.00127	0.00207	CcSEcCtD
Molindone—Dysphagia—Capecitabine—prostate cancer	0.00125	0.00205	CcSEcCtD
Molindone—Salivary hypersecretion—Doxorubicin—prostate cancer	0.00125	0.00204	CcSEcCtD
Molindone—Constipation—Goserelin—prostate cancer	0.00123	0.00201	CcSEcCtD
Molindone—Nausea—Bicalutamide—prostate cancer	0.00123	0.00201	CcSEcCtD
Molindone—Vision blurred—Mitoxantrone—prostate cancer	0.00123	0.00201	CcSEcCtD
Molindone—Constipation—Conjugated Estrogens—prostate cancer	0.00122	0.00199	CcSEcCtD
Molindone—Weight increased—Docetaxel—prostate cancer	0.00118	0.00192	CcSEcCtD
Molindone—Weight decreased—Docetaxel—prostate cancer	0.00117	0.00191	CcSEcCtD
Molindone—Leukopenia—Mitoxantrone—prostate cancer	0.00117	0.00191	CcSEcCtD
Molindone—Dry mouth—Estradiol—prostate cancer	0.00117	0.0019	CcSEcCtD
Molindone—Weight increased—Capecitabine—prostate cancer	0.00114	0.00186	CcSEcCtD
Molindone—Weight decreased—Capecitabine—prostate cancer	0.00113	0.00185	CcSEcCtD
Molindone—Tachycardia—Estradiol—prostate cancer	0.00112	0.00182	CcSEcCtD
Molindone—Rash—Ethinyl Estradiol—prostate cancer	0.00111	0.0018	CcSEcCtD
Molindone—Dermatitis—Ethinyl Estradiol—prostate cancer	0.0011	0.0018	CcSEcCtD
Molindone—Muscle spasms—Etoposide—prostate cancer	0.00104	0.0017	CcSEcCtD
Molindone—Nausea—Ethinyl Estradiol—prostate cancer	0.00104	0.0017	CcSEcCtD
Molindone—Tachycardia—Mitoxantrone—prostate cancer	0.00104	0.0017	CcSEcCtD
Molindone—Dyspnoea—Estradiol—prostate cancer	0.00102	0.00166	CcSEcCtD
Molindone—Somnolence—Estradiol—prostate cancer	0.00102	0.00166	CcSEcCtD
Molindone—Weight increased—Prednisone—prostate cancer	0.00102	0.00166	CcSEcCtD
Molindone—Weight decreased—Prednisone—prostate cancer	0.00101	0.00165	CcSEcCtD
Molindone—Hypotension—Mitoxantrone—prostate cancer	0.000996	0.00162	CcSEcCtD
Molindone—Constipation—Estradiol—prostate cancer	0.000978	0.0016	CcSEcCtD
Molindone—Leukopenia—Etoposide—prostate cancer	0.000972	0.00159	CcSEcCtD
Molindone—Dyspnoea—Mitoxantrone—prostate cancer	0.00095	0.00155	CcSEcCtD
Molindone—Somnolence—Mitoxantrone—prostate cancer	0.000947	0.00155	CcSEcCtD
Molindone—Constipation—Mitoxantrone—prostate cancer	0.000911	0.00149	CcSEcCtD
Molindone—Rash—Goserelin—prostate cancer	0.00091	0.00148	CcSEcCtD
Molindone—Dermatitis—Goserelin—prostate cancer	0.000909	0.00148	CcSEcCtD
Molindone—Rash—Conjugated Estrogens—prostate cancer	0.000901	0.00147	CcSEcCtD
Molindone—Dermatitis—Conjugated Estrogens—prostate cancer	0.0009	0.00147	CcSEcCtD
Molindone—Dysphagia—Epirubicin—prostate cancer	0.000874	0.00143	CcSEcCtD
Molindone—Muscle spasms—Docetaxel—prostate cancer	0.000868	0.00142	CcSEcCtD
Molindone—Tachycardia—Etoposide—prostate cancer	0.000865	0.00141	CcSEcCtD
Molindone—Nausea—Goserelin—prostate cancer	0.000857	0.0014	CcSEcCtD
Molindone—Nausea—Conjugated Estrogens—prostate cancer	0.000849	0.00138	CcSEcCtD
Molindone—Muscle spasms—Capecitabine—prostate cancer	0.00084	0.00137	CcSEcCtD
Molindone—Hypotension—Etoposide—prostate cancer	0.000828	0.00135	CcSEcCtD
Molindone—Vision blurred—Capecitabine—prostate cancer	0.000824	0.00134	CcSEcCtD
Molindone—Tremor—Capecitabine—prostate cancer	0.000819	0.00134	CcSEcCtD
Molindone—Dysphagia—Doxorubicin—prostate cancer	0.000808	0.00132	CcSEcCtD
Molindone—Leukopenia—Docetaxel—prostate cancer	0.000808	0.00132	CcSEcCtD
Molindone—Weight increased—Epirubicin—prostate cancer	0.000795	0.0013	CcSEcCtD
Molindone—Weight decreased—Epirubicin—prostate cancer	0.00079	0.00129	CcSEcCtD
Molindone—Dyspnoea—Etoposide—prostate cancer	0.00079	0.00129	CcSEcCtD
Molindone—Somnolence—Etoposide—prostate cancer	0.000788	0.00129	CcSEcCtD
Molindone—Leukopenia—Capecitabine—prostate cancer	0.000782	0.00128	CcSEcCtD
Molindone—Drowsiness—Epirubicin—prostate cancer	0.000779	0.00127	CcSEcCtD
Molindone—Constipation—Etoposide—prostate cancer	0.000758	0.00124	CcSEcCtD
Molindone—Dry mouth—Docetaxel—prostate cancer	0.000751	0.00123	CcSEcCtD
Molindone—Weight increased—Doxorubicin—prostate cancer	0.000736	0.0012	CcSEcCtD
Molindone—Vision blurred—Prednisone—prostate cancer	0.000734	0.0012	CcSEcCtD
Molindone—Weight decreased—Doxorubicin—prostate cancer	0.000731	0.00119	CcSEcCtD
Molindone—Dry mouth—Capecitabine—prostate cancer	0.000728	0.00119	CcSEcCtD
Molindone—Rash—Estradiol—prostate cancer	0.000721	0.00118	CcSEcCtD
Molindone—Drowsiness—Doxorubicin—prostate cancer	0.000721	0.00118	CcSEcCtD
Molindone—Dermatitis—Estradiol—prostate cancer	0.00072	0.00118	CcSEcCtD
Molindone—Tachycardia—Docetaxel—prostate cancer	0.000719	0.00117	CcSEcCtD
Molindone—Agitation—Prednisone—prostate cancer	0.000715	0.00117	CcSEcCtD
Molindone—Tachycardia—Capecitabine—prostate cancer	0.000696	0.00114	CcSEcCtD
Molindone—Hypotension—Docetaxel—prostate cancer	0.000688	0.00112	CcSEcCtD
Molindone—Nausea—Estradiol—prostate cancer	0.000679	0.00111	CcSEcCtD
Molindone—Rash—Mitoxantrone—prostate cancer	0.000672	0.0011	CcSEcCtD
Molindone—Dermatitis—Mitoxantrone—prostate cancer	0.000671	0.0011	CcSEcCtD
Molindone—Hypotension—Capecitabine—prostate cancer	0.000666	0.00109	CcSEcCtD
Molindone—Dyspnoea—Docetaxel—prostate cancer	0.000657	0.00107	CcSEcCtD
Molindone—Somnolence—Docetaxel—prostate cancer	0.000655	0.00107	CcSEcCtD
Molindone—Dyspnoea—Capecitabine—prostate cancer	0.000636	0.00104	CcSEcCtD
Molindone—Nausea—Mitoxantrone—prostate cancer	0.000633	0.00103	CcSEcCtD
Molindone—Constipation—Docetaxel—prostate cancer	0.00063	0.00103	CcSEcCtD
Molindone—Tachycardia—Prednisone—prostate cancer	0.00062	0.00101	CcSEcCtD
Molindone—Constipation—Capecitabine—prostate cancer	0.00061	0.000995	CcSEcCtD
Molindone—Muscle spasms—Epirubicin—prostate cancer	0.000585	0.000955	CcSEcCtD
Molindone—Vision blurred—Epirubicin—prostate cancer	0.000574	0.000936	CcSEcCtD
Molindone—Agitation—Epirubicin—prostate cancer	0.000559	0.000913	CcSEcCtD
Molindone—Rash—Etoposide—prostate cancer	0.000559	0.000912	CcSEcCtD
Molindone—Dermatitis—Etoposide—prostate cancer	0.000558	0.000911	CcSEcCtD
Molindone—Leukopenia—Epirubicin—prostate cancer	0.000545	0.000889	CcSEcCtD
Molindone—Constipation—Prednisone—prostate cancer	0.000543	0.000886	CcSEcCtD
Molindone—Muscle spasms—Doxorubicin—prostate cancer	0.000542	0.000884	CcSEcCtD
Molindone—Vision blurred—Doxorubicin—prostate cancer	0.000531	0.000866	CcSEcCtD
Molindone—Nausea—Etoposide—prostate cancer	0.000526	0.000859	CcSEcCtD
Molindone—Agitation—Doxorubicin—prostate cancer	0.000518	0.000845	CcSEcCtD
Molindone—Dry mouth—Epirubicin—prostate cancer	0.000507	0.000827	CcSEcCtD
Molindone—Leukopenia—Doxorubicin—prostate cancer	0.000504	0.000823	CcSEcCtD
Molindone—Tachycardia—Epirubicin—prostate cancer	0.000485	0.000791	CcSEcCtD
Molindone—Dry mouth—Doxorubicin—prostate cancer	0.000469	0.000765	CcSEcCtD
Molindone—Rash—Docetaxel—prostate cancer	0.000464	0.000758	CcSEcCtD
Molindone—Hypotension—Epirubicin—prostate cancer	0.000464	0.000758	CcSEcCtD
Molindone—Dermatitis—Docetaxel—prostate cancer	0.000464	0.000757	CcSEcCtD
Molindone—Rash—Capecitabine—prostate cancer	0.00045	0.000734	CcSEcCtD
Molindone—Dermatitis—Capecitabine—prostate cancer	0.000449	0.000733	CcSEcCtD
Molindone—Tachycardia—Doxorubicin—prostate cancer	0.000449	0.000732	CcSEcCtD
Molindone—Dyspnoea—Epirubicin—prostate cancer	0.000443	0.000723	CcSEcCtD
Molindone—Somnolence—Epirubicin—prostate cancer	0.000442	0.000721	CcSEcCtD
Molindone—Nausea—Docetaxel—prostate cancer	0.000438	0.000714	CcSEcCtD
Molindone—Hypotension—Doxorubicin—prostate cancer	0.00043	0.000701	CcSEcCtD
Molindone—Constipation—Epirubicin—prostate cancer	0.000425	0.000693	CcSEcCtD
Molindone—Nausea—Capecitabine—prostate cancer	0.000424	0.000691	CcSEcCtD
Molindone—Dyspnoea—Doxorubicin—prostate cancer	0.00041	0.000669	CcSEcCtD
Molindone—Somnolence—Doxorubicin—prostate cancer	0.000409	0.000667	CcSEcCtD
Molindone—Rash—Prednisone—prostate cancer	0.000401	0.000654	CcSEcCtD
Molindone—Dermatitis—Prednisone—prostate cancer	0.0004	0.000653	CcSEcCtD
Molindone—Constipation—Doxorubicin—prostate cancer	0.000393	0.000641	CcSEcCtD
Molindone—Nausea—Prednisone—prostate cancer	0.000377	0.000616	CcSEcCtD
Molindone—Rash—Epirubicin—prostate cancer	0.000313	0.000511	CcSEcCtD
Molindone—Dermatitis—Epirubicin—prostate cancer	0.000313	0.000511	CcSEcCtD
Molindone—Nausea—Epirubicin—prostate cancer	0.000295	0.000482	CcSEcCtD
Molindone—Rash—Doxorubicin—prostate cancer	0.00029	0.000473	CcSEcCtD
Molindone—Dermatitis—Doxorubicin—prostate cancer	0.00029	0.000473	CcSEcCtD
Molindone—Nausea—Doxorubicin—prostate cancer	0.000273	0.000446	CcSEcCtD
Molindone—HTR7—Signaling Pathways—CDKN1A—prostate cancer	2.31e-05	9.45e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—PTEN—prostate cancer	2.3e-05	9.42e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—HIF1A—prostate cancer	2.3e-05	9.41e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—BAD—prostate cancer	2.3e-05	9.41e-05	CbGpPWpGaD
Molindone—ADRA2A—Metabolism—INS—prostate cancer	2.29e-05	9.39e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—BAD—prostate cancer	2.29e-05	9.36e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—MAP2K1—prostate cancer	2.28e-05	9.33e-05	CbGpPWpGaD
Molindone—ADRA2A—Hemostasis—AKT1—prostate cancer	2.28e-05	9.33e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—PIK3CD—prostate cancer	2.27e-05	9.27e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—APC—prostate cancer	2.26e-05	9.26e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—PIK3CG—prostate cancer	2.26e-05	9.26e-05	CbGpPWpGaD
Molindone—HTR7—Signaling by GPCR—AKT1—prostate cancer	2.25e-05	9.19e-05	CbGpPWpGaD
Molindone—ADRA2A—Metabolism—CREBBP—prostate cancer	2.25e-05	9.19e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—LEP—prostate cancer	2.25e-05	9.19e-05	CbGpPWpGaD
Molindone—HTR1A—GPCR downstream signaling—PIK3CA—prostate cancer	2.25e-05	9.18e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—SERPINE1—prostate cancer	2.24e-05	9.17e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—EGF—prostate cancer	2.24e-05	9.15e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—IRS1—prostate cancer	2.24e-05	9.15e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—PIK3CG—prostate cancer	2.23e-05	9.11e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—APC—prostate cancer	2.23e-05	9.11e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—CAV1—prostate cancer	2.23e-05	9.1e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling by GPCR—KRAS—prostate cancer	2.22e-05	9.08e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—PIK3CG—prostate cancer	2.22e-05	9.06e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—APC—prostate cancer	2.22e-05	9.06e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—IRS1—prostate cancer	2.2e-05	9.01e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—EGF—prostate cancer	2.2e-05	9.01e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—KDR—prostate cancer	2.2e-05	9e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—EP300—prostate cancer	2.2e-05	8.99e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—EGF—prostate cancer	2.19e-05	8.96e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—IRS1—prostate cancer	2.19e-05	8.96e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—GSK3B—prostate cancer	2.17e-05	8.89e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—FGF2—prostate cancer	2.17e-05	8.88e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—ESR1—prostate cancer	2.14e-05	8.77e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—INS—prostate cancer	2.14e-05	8.77e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—NOS3—prostate cancer	2.14e-05	8.76e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—GSK3B—prostate cancer	2.14e-05	8.74e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—SRC—prostate cancer	2.14e-05	8.74e-05	CbGpPWpGaD
Molindone—ADRA2A—Metabolism—PIK3CD—prostate cancer	2.13e-05	8.72e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—GSK3B—prostate cancer	2.13e-05	8.7e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—INS—prostate cancer	2.11e-05	8.63e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—CREBBP—prostate cancer	2.1e-05	8.59e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—INS—prostate cancer	2.1e-05	8.58e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—BAD—prostate cancer	2.09e-05	8.56e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—VEGFA—prostate cancer	2.08e-05	8.51e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—JAK2—prostate cancer	2.08e-05	8.51e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—IGF1—prostate cancer	2.07e-05	8.48e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—CREBBP—prostate cancer	2.07e-05	8.45e-05	CbGpPWpGaD
Molindone—DRD2—Signaling by GPCR—EGFR—prostate cancer	2.06e-05	8.44e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—STAT3—prostate cancer	2.06e-05	8.43e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—CREBBP—prostate cancer	2.05e-05	8.4e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—IGF1—prostate cancer	2.04e-05	8.34e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling by GPCR—PIK3CA—prostate cancer	2.04e-05	8.34e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—MDM2—prostate cancer	2.03e-05	8.31e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling by GPCR—EGFR—prostate cancer	2.03e-05	8.3e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—IGF1—prostate cancer	2.03e-05	8.3e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—APC—prostate cancer	2.03e-05	8.29e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	2.03e-05	8.29e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling by GPCR—EGFR—prostate cancer	2.02e-05	8.26e-05	CbGpPWpGaD
Molindone—ADRA2A—Metabolism—NOS3—prostate cancer	2.01e-05	8.23e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—MAP2K1—prostate cancer	2e-05	8.2e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—EGF—prostate cancer	2e-05	8.2e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—IRS1—prostate cancer	2e-05	8.2e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—ERBB2—prostate cancer	2e-05	8.19e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—PIK3CD—prostate cancer	1.99e-05	8.14e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—PIK3CB—prostate cancer	1.98e-05	8.08e-05	CbGpPWpGaD
Molindone—DRD2—GPCR downstream signaling—PIK3CA—prostate cancer	1.97e-05	8.06e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—MAP2K1—prostate cancer	1.97e-05	8.06e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—SERPINE1—prostate cancer	1.97e-05	8.05e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	1.96e-05	8.02e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—PIK3CD—prostate cancer	1.96e-05	8.01e-05	CbGpPWpGaD
Molindone—DRD2—Signaling by GPCR—KRAS—prostate cancer	1.95e-05	7.97e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	1.95e-05	7.97e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	1.95e-05	7.96e-05	CbGpPWpGaD
Molindone—HTR2A—GPCR downstream signaling—PIK3CA—prostate cancer	1.94e-05	7.93e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—SERPINE1—prostate cancer	1.94e-05	7.92e-05	CbGpPWpGaD
Molindone—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	1.93e-05	7.89e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	1.93e-05	7.88e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—INS—prostate cancer	1.92e-05	7.85e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling by GPCR—KRAS—prostate cancer	1.92e-05	7.84e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—MYC—prostate cancer	1.92e-05	7.83e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—TGFB1—prostate cancer	1.91e-05	7.81e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling by GPCR—KRAS—prostate cancer	1.91e-05	7.8e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—FGF2—prostate cancer	1.91e-05	7.8e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—CXCL8—prostate cancer	1.9e-05	7.77e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—NOS3—prostate cancer	1.88e-05	7.69e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	1.88e-05	7.69e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—FGF2—prostate cancer	1.88e-05	7.67e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—EGFR—prostate cancer	1.87e-05	7.66e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—FGF2—prostate cancer	1.87e-05	7.63e-05	CbGpPWpGaD
Molindone—ADRA2A—Metabolism—PIK3CB—prostate cancer	1.86e-05	7.6e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—IGF1—prostate cancer	1.86e-05	7.59e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—CDKN1B—prostate cancer	1.85e-05	7.59e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—NOS3—prostate cancer	1.85e-05	7.56e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	1.85e-05	7.55e-05	CbGpPWpGaD
Molindone—ADRA2A—Metabolism—PTGS2—prostate cancer	1.84e-05	7.53e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—NOS3—prostate cancer	1.84e-05	7.52e-05	CbGpPWpGaD
Molindone—HTR1A—GPCR downstream signaling—AKT1—prostate cancer	1.83e-05	7.5e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—JAK2—prostate cancer	1.83e-05	7.47e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—CASP3—prostate cancer	1.82e-05	7.43e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—IL2—prostate cancer	1.81e-05	7.42e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling by GPCR—IL6—prostate cancer	1.81e-05	7.39e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—JAK2—prostate cancer	1.8e-05	7.35e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	1.79e-05	7.34e-05	CbGpPWpGaD
Molindone—DRD2—Signaling by GPCR—PIK3CA—prostate cancer	1.79e-05	7.32e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—JAK2—prostate cancer	1.79e-05	7.31e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—MDM2—prostate cancer	1.78e-05	7.29e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	1.78e-05	7.29e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—KRAS—prostate cancer	1.77e-05	7.24e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—CCND1—prostate cancer	1.77e-05	7.24e-05	CbGpPWpGaD
Molindone—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	1.77e-05	7.22e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	1.76e-05	7.21e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	1.76e-05	7.21e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—ERBB2—prostate cancer	1.76e-05	7.19e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—MDM2—prostate cancer	1.75e-05	7.18e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	1.75e-05	7.17e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	1.75e-05	7.17e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—MDM2—prostate cancer	1.75e-05	7.14e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	1.74e-05	7.14e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—PIK3CB—prostate cancer	1.74e-05	7.1e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—ERBB2—prostate cancer	1.73e-05	7.08e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—ERBB2—prostate cancer	1.72e-05	7.04e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—MMP9—prostate cancer	1.72e-05	7.03e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	1.71e-05	7e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—PTEN—prostate cancer	1.71e-05	6.98e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	1.71e-05	6.98e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—FGF2—prostate cancer	1.71e-05	6.98e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	1.7e-05	6.95e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—NOS3—prostate cancer	1.68e-05	6.88e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—CXCL8—prostate cancer	1.67e-05	6.82e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling by GPCR—AKT1—prostate cancer	1.67e-05	6.81e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—CXCL8—prostate cancer	1.64e-05	6.71e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—JAK2—prostate cancer	1.64e-05	6.69e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—CXCL8—prostate cancer	1.63e-05	6.67e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—EP300—prostate cancer	1.63e-05	6.66e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—CDKN1B—prostate cancer	1.63e-05	6.66e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—PIK3CA—prostate cancer	1.63e-05	6.65e-05	CbGpPWpGaD
Molindone—DRD2—GPCR downstream signaling—AKT1—prostate cancer	1.61e-05	6.59e-05	CbGpPWpGaD
Molindone—ADRA2A—Metabolism—PTEN—prostate cancer	1.61e-05	6.56e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	1.6e-05	6.56e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	1.6e-05	6.55e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—MDM2—prostate cancer	1.6e-05	6.53e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—CASP3—prostate cancer	1.6e-05	6.53e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	1.59e-05	6.52e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—IL2—prostate cancer	1.59e-05	6.52e-05	CbGpPWpGaD
Molindone—DRD2—Signaling by GPCR—IL6—prostate cancer	1.59e-05	6.48e-05	CbGpPWpGaD
Molindone—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	1.58e-05	6.48e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—SRC—prostate cancer	1.58e-05	6.48e-05	CbGpPWpGaD
Molindone—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	1.58e-05	6.45e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	1.57e-05	6.44e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—TP53—prostate cancer	1.57e-05	6.43e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—CASP3—prostate cancer	1.57e-05	6.42e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—IL2—prostate cancer	1.57e-05	6.41e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—CASP3—prostate cancer	1.56e-05	6.39e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling by GPCR—IL6—prostate cancer	1.56e-05	6.38e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—IL2—prostate cancer	1.56e-05	6.38e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—CCND1—prostate cancer	1.55e-05	6.35e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	1.55e-05	6.35e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling by GPCR—IL6—prostate cancer	1.55e-05	6.35e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—VEGFA—prostate cancer	1.54e-05	6.31e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—CTNNB1—prostate cancer	1.54e-05	6.29e-05	CbGpPWpGaD
Molindone—ADRA2A—Metabolism—EP300—prostate cancer	1.53e-05	6.26e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—CCND1—prostate cancer	1.53e-05	6.25e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—STAT3—prostate cancer	1.53e-05	6.25e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—CCND1—prostate cancer	1.52e-05	6.22e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	1.51e-05	6.19e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—MMP9—prostate cancer	1.51e-05	6.17e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	1.51e-05	6.16e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—CDKN1A—prostate cancer	1.5e-05	6.15e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—PTEN—prostate cancer	1.5e-05	6.13e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	1.49e-05	6.1e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—MMP9—prostate cancer	1.48e-05	6.07e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	1.48e-05	6.05e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—MMP9—prostate cancer	1.48e-05	6.04e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—PTEN—prostate cancer	1.48e-05	6.03e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	1.47e-05	6.02e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—PTEN—prostate cancer	1.47e-05	6e-05	CbGpPWpGaD
Molindone—DRD2—Signaling by GPCR—AKT1—prostate cancer	1.46e-05	5.98e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	1.46e-05	5.96e-05	CbGpPWpGaD
Molindone—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	1.44e-05	5.9e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—IL6—prostate cancer	1.44e-05	5.89e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling by GPCR—AKT1—prostate cancer	1.44e-05	5.89e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling by GPCR—AKT1—prostate cancer	1.43e-05	5.85e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—EP300—prostate cancer	1.43e-05	5.85e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—CASP3—prostate cancer	1.43e-05	5.84e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—IL2—prostate cancer	1.43e-05	5.83e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling by GPCR—IL6—prostate cancer	1.42e-05	5.8e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—MYC—prostate cancer	1.42e-05	5.8e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—TGFB1—prostate cancer	1.42e-05	5.79e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—EP300—prostate cancer	1.41e-05	5.75e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—EP300—prostate cancer	1.4e-05	5.72e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—CCND1—prostate cancer	1.39e-05	5.69e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—SRC—prostate cancer	1.39e-05	5.69e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—EGFR—prostate cancer	1.39e-05	5.68e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	1.38e-05	5.63e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—SRC—prostate cancer	1.37e-05	5.6e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—SRC—prostate cancer	1.36e-05	5.57e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—VEGFA—prostate cancer	1.35e-05	5.54e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—MMP9—prostate cancer	1.35e-05	5.52e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	1.35e-05	5.5e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—PTEN—prostate cancer	1.34e-05	5.49e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—STAT3—prostate cancer	1.34e-05	5.48e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—VEGFA—prostate cancer	1.33e-05	5.45e-05	CbGpPWpGaD
Molindone—HTR7—Signaling Pathways—AKT1—prostate cancer	1.33e-05	5.43e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—VEGFA—prostate cancer	1.33e-05	5.42e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—STAT3—prostate cancer	1.32e-05	5.4e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—STAT3—prostate cancer	1.31e-05	5.37e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—KRAS—prostate cancer	1.31e-05	5.36e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	1.31e-05	5.36e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—EP300—prostate cancer	1.28e-05	5.24e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—MYC—prostate cancer	1.25e-05	5.1e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—SRC—prostate cancer	1.24e-05	5.09e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—TGFB1—prostate cancer	1.24e-05	5.08e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—MYC—prostate cancer	1.23e-05	5.01e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—TGFB1—prostate cancer	1.22e-05	5e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—MYC—prostate cancer	1.22e-05	4.99e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—EGFR—prostate cancer	1.22e-05	4.98e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—TGFB1—prostate cancer	1.22e-05	4.98e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	1.21e-05	4.96e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	1.2e-05	4.93e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—STAT3—prostate cancer	1.2e-05	4.91e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—EGFR—prostate cancer	1.2e-05	4.9e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—EGFR—prostate cancer	1.19e-05	4.88e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—TP53—prostate cancer	1.17e-05	4.77e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—KRAS—prostate cancer	1.15e-05	4.71e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—KRAS—prostate cancer	1.13e-05	4.63e-05	CbGpPWpGaD
Molindone—ADRA2A—Metabolism—PIK3CA—prostate cancer	1.13e-05	4.63e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—KRAS—prostate cancer	1.13e-05	4.61e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—MYC—prostate cancer	1.12e-05	4.56e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	1.11e-05	4.55e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—EGFR—prostate cancer	1.09e-05	4.46e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—IL6—prostate cancer	1.07e-05	4.36e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—PIK3CA—prostate cancer	1.06e-05	4.33e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	1.04e-05	4.26e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	1.04e-05	4.23e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—KRAS—prostate cancer	1.03e-05	4.22e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—TP53—prostate cancer	1.02e-05	4.19e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—TP53—prostate cancer	1.01e-05	4.12e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—TP53—prostate cancer	1e-05	4.1e-05	CbGpPWpGaD
Molindone—HTR1A—Signaling Pathways—AKT1—prostate cancer	9.84e-06	4.03e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	9.47e-06	3.87e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—IL6—prostate cancer	9.37e-06	3.83e-05	CbGpPWpGaD
Molindone—ADRA2A—Metabolism—AKT1—prostate cancer	9.25e-06	3.78e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—IL6—prostate cancer	9.22e-06	3.77e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—IL6—prostate cancer	9.17e-06	3.75e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—TP53—prostate cancer	9.16e-06	3.75e-05	CbGpPWpGaD
Molindone—DRD2—Signaling Pathways—AKT1—prostate cancer	8.64e-06	3.53e-05	CbGpPWpGaD
Molindone—HTR2A—Signaling Pathways—AKT1—prostate cancer	8.5e-06	3.48e-05	CbGpPWpGaD
Molindone—CHRM1—Signaling Pathways—AKT1—prostate cancer	8.46e-06	3.46e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—IL6—prostate cancer	8.38e-06	3.43e-05	CbGpPWpGaD
Molindone—ADRA2A—Signaling Pathways—AKT1—prostate cancer	7.74e-06	3.16e-05	CbGpPWpGaD
